CORNERSTONE THERAPEUTICS INC Form 8-K April 07, 2009

Table of Contents

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 1, 2009 Cornerstone Therapeutics Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware000-5076704-3523569(State or Other Jurisdiction
of Incorporation)(Commission
File Number)(IRS Employer
Identification No.)

1255 Crescent Green Drive, Suite 250, Cary, NC

27518

(Address of Principal Executive Offices)

(Zip Code)

Registrant s telephone number, including area code: (919) 678-6611

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

TABLE OF CONTENTS

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain

Officers; Compensatory Arrangements of Certain Officers

Item 9.01. Financial Statements and Exhibits

SIGNATURE

EXHIBIT INDEX

Ex-99.1 Press Release dated April 7, 2009

Table of Contents

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 1, 2009, Cornerstone Therapeutics Inc. (the Company) was notified by Chenyqua M. Baldwin, the Company s Vice President, Finance, Chief Accounting Officer and Controller, that she intends to leave the Company on or about May 6, 2009 to pursue other opportunities.

A copy of the Company s press release announcing Ms. Baldwin s resignation from the Company is attached as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

See the Exhibit Index attached hereto.

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CORNERSTONE THERAPEUTICS INC.

Date: April 7, 2009 By: /s/ Craig A. Collard

Craig A. Collard

President and Chief Executive Officer

Table of Contents

EXHIBIT INDEX

Exhibit No. Description of Document

Exhibit 99.1 Press Release of Cornerstone Therapeutics Inc. dated April 7, 2009.